These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 32596372)

  • 1. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma.
    Jin D; Song Y; Chen Y; Zhang P
    Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
    Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
    BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of hypoxia-associated lncRNA signature to predict prognosis and immune microenvironment of lung adenocarcinoma patients.
    Shao J; Zhang B; Kuai L; Li Q
    Bioengineered; 2021 Dec; 12(1):6186-6200. PubMed ID: 34486476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
    Ren J; Wang A; Liu J; Yuan Q
    Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
    Wang Z; Chen X
    Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients.
    Liu J; Wu H; Gao Z; Lou M; Yuan K
    Bioengineered; 2021 Dec; 12(1):4123-4135. PubMed ID: 34288805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
    Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
    Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma.
    Song J; Sun Y; Cao H; Liu Z; Xi L; Dong C; Yang R; Shi Y
    Bioengineered; 2021 Dec; 12(1):5932-5949. PubMed ID: 34488540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma.
    Chen Y; Zhang X; Li J; Zhou M
    J Clin Lab Anal; 2021 Nov; 35(11):e24018. PubMed ID: 34550610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
    Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
    J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
    Ma C; Gu Z; Yang Y
    J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
    Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
    BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
    You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
    Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of six immune-related lncRNA signature prognostic model for smoking-positive lung adenocarcinoma.
    Zhou D; Wang J; Liu X
    J Clin Lab Anal; 2022 Jun; 36(6):e24467. PubMed ID: 35561270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.